Citius Pharmaceuticals
CTXR
30 hedge funds and large institutions have $2.43M invested in Citius Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 34 closing their positions.
137% more call options, than puts
Call options by funds: $244K | Put options by funds: $103K
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
7.75% more ownership
Funds ownership: 0.52% → 8.27% (+7.8%)
47% less funds holding
Funds holding: 57 → 30 (-27)
79% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 34
79% less capital invested
Capital invested by funds: $11.8M → $2.43M (-$9.38M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
+$263K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$186K |
| 3 |
Squarepoint
New York
|
+$157K |
| 4 |
Fisher Asset Management
Camas,
Washington
|
+$86.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$54.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.64M |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$241K |
| 3 |
CCC
Chelsea Counsel Company
Los Angeles,
California
|
-$141K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$107K |
| 5 |
WAS
Wealth Advisory Solutions
Indiianapolis,
Indiana
|
-$101K |
CTXR Hedge Fund Activity: Q4 2024 in Review
30 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q4 2024, worth a combined $2.43M — down 79% from $11.8M a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of CTXR and 7 opened new positions — a net loss of 27 holders — while 9 trimmed existing stakes and 11 added.
The largest buyer was IFP Advisors, adding an estimated $263K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.64M sold.
- 30 institutional investors held Citius Pharmaceuticals (CTXR) as of Q4 2024, down from 57 in Q3 2024.
- Funds reported $2.43M of Citius Pharmaceuticals stock for Q4 2024, down 79% quarter-over-quarter.
- 7 funds opened new Citius Pharmaceuticals positions in Q4 2024 and 34 closed out, a net change of -27 holders.
- The largest Citius Pharmaceuticals buyer in Q4 2024 was IFP Advisors, an estimated $263K added.
- The largest Citius Pharmaceuticals seller in Q4 2024 was Armistice Capital, an estimated $3.64M sold.
Based on aggregated 13F filings for Q4 2024.